Angiotensin II in Decompensated Cirrhosis Complicated by Septic Shock

作者：Patrick J. Coleman, Alexander P. Nissen, Daniel E Kim, Craig Ainsworth, Michael T. McCurdy, Michael Mazzeffi, Jonathan H. Chow · 发表于：Seminars in Cardiothoracic and Vascular Anesthesia · 年份：2019 · DOI：10.1177/1089253219877876 · 被引用次数：17 · 研究领域：Sepsis Diagnosis and Treatment、Liver Disease and Transplantation、Electrolyte and hormonal disorders

This case describes the first reported use of human-derived synthetic angiotensin II (Ang-2) in a patient with decompensated cirrhosis and septic shock. The patient presented in vasodilatory shock from Enterobacter cloacae bacteremia with a Sequential Organ Failure Assessment Score of 14 and a Model for End-Stage Liver Disease score of 36. This case is significant because liver failure was an exclusion criterion in the Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) trial, but the liver produces angiotensinogen, which is key precursor to Ang-2 in the renin-angiotensin-aldosterone system. Resuscitation with Ang-2 is a potentially beneficial medication when conventional vasopressors have failed to control mean arterial pressure in this population.